Associated Papers
Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia.
Mangoura SA et al.
Cancer Chemotherapy and Pharmacology, 2024
The Cytochrome P450 2C8*3 Variant (rs11572080) Is Associated with Improved Asthma Symptom Control in Children and Altered Lipid Mediator Production and Inflammatory Response in Human Bronchial Epithelial Cells.
Almestica-Roberts M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2024
Distribution of CYP2C8 and CYP2C9 amino acid substitution alleles in South Indian diabetes patients: A genotypic and computational protein phenotype study.
Rao DK et al.
Clinical and Experimental Pharmacology & Physiology, 2017
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals.
Yin SJ et al.
Pharmacogenetics and Genomics, 2017
Pharmacogenetics in Jewish populations.
Yang Y et al.
Drug Metabolism and Drug Interactions, 2014
Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.
Martis S et al.
The Pharmacogenomics Journal, 2013
Prevalence of CYP2C8 polymorphisms in a North Indian population.
Minhas S et al.
Genetics and Molecular Research : Gmr, 2013
Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population.
Arnaldo P et al.
The Malaysian Journal of Medical Sciences : Mjms, 2013
CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease.
Musumba CO et al.
Clinical Pharmacology and Therapeutics, 2013
Genetic polymorphisms of CYP2C8 in the Czech Republic.
Pechandova K et al.
Genetic Testing and Molecular Biomarkers, 2012
Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients.
Seredina TA et al.
Bmc Medical Genetics, 2012
A bioinformatics approach for the phenotype prediction of nonsynonymous single nucleotide polymorphisms in human cytochromes P450.
Wang LL et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes?
Singh V et al.
Cancer Investigation, 2008
Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers.
Aquilante CL et al.
Human Genomics, 2008
Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism.
Rodríguez-Antona C et al.
The Pharmacogenomics Journal, 2008
Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa.
Parikh S et al.
Clinical Pharmacology and Therapeutics, 2007
A novel intronic mutation that may affect genotyping result of CYP2C8 by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) is strongly associated with CYP2C8*3 in a South American population.
Bravo-Villalta HV et al.
Journal of Human Genetics, 2007
Predicting drug response and toxicity based on gene polymorphisms.
Robert J et al.
Critical Reviews in Oncology/hematology, 2005
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Niemi M et al.
Clinical Pharmacology and Therapeutics, 2005
A simple multiplex PCR method for the concurrent detection of three CYP2C8 variants.
Muthiah YD et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2004